Pacific Biosciences
PACB
207 hedge funds and large institutions have $246M invested in Pacific Biosciences in 2025 Q2 according to their latest regulatory filings, with 30 funds opening new positions, 53 increasing their positions, 72 reducing their positions, and 46 closing their positions.
7% less capital invested
Capital invested by funds: $266M → $246M (-$19.7M)
8% less funds holding
Funds holding: 225 → 207 (-18)
9.47% less ownership
Funds ownership: 75.6% → 66.14% (-9.5%)
18% less call options, than puts
Call options by funds: $2.16M | Put options by funds: $2.62M
26% less repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 72
35% less first-time investments, than exits
New positions opened: 30 | Existing positions closed: 46
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Amiral Gestion
Paris,
France
|
+$3.16M |
| 2 |
PD
Point72 (DIFC)
Dubai,
United Arab Emirates
|
+$2.84M |
| 3 |
PEAK6
Chicago,
Illinois
|
+$1.15M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.08M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$1.06M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EDRH
Edmond de Rothschild Holding
Chambesy,
Switzerland
|
-$9.8M |
| 2 |
MA
Madrone Advisors
Menlo Park,
California
|
-$7.66M |
| 3 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$5.64M |
| 4 |
JSP
Jackson Square Partners
Larkspur,
California
|
-$3.2M |
| 5 |
Morgan Stanley
New York
|
-$2.93M |
PACB Hedge Fund Activity: Q2 2025 in Review
207 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Pacific Biosciences (PACB) for Q2 2025, worth a combined $246M — down 7.4% from $266M a quarter earlier.
Sellers outnumbered buyers: 46 funds closed out of PACB and 30 opened new positions — a net loss of 16 holders — while 72 trimmed existing stakes and 53 added.
The largest buyer was Amiral Gestion, opening a new position worth an estimated $3.16M. The largest seller was Edmond de Rothschild Holding, cutting an estimated $9.8M.
- 207 institutional investors held Pacific Biosciences (PACB) as of Q2 2025, down from 225 in Q1 2025.
- Funds reported $246M of Pacific Biosciences stock for Q2 2025, down 7.4% quarter-over-quarter.
- 30 funds opened new Pacific Biosciences positions in Q2 2025 and 46 closed out, a net change of -16 holders.
- The largest Pacific Biosciences buyer in Q2 2025 was Amiral Gestion, an estimated $3.16M added.
- The largest Pacific Biosciences seller in Q2 2025 was Edmond de Rothschild Holding, an estimated $9.8M sold.
Based on aggregated 13F filings for Q2 2025.